Liquid biopsy for rectal cancer: A systematic review.

[1]  P. Laurent-Puig,et al.  The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer , 2019, Drugs.

[2]  N. Baxter,et al.  Looking Forward, Not Backward, on Watch and Wait for Rectal Cancer. , 2019, JAMA Oncology.

[3]  Lijun Shen,et al.  ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with ‘watch and wait’ approach. , 2019, Journal of Clinical Oncology.

[4]  X. Yi,et al.  Serial ctDNA analysis as a real-time indicator of neoadjuvant chemoradiotherapy in rectal cancer. , 2019, Journal of Clinical Oncology.

[5]  A. Sartore-Bianchi,et al.  Treatment sequencing in metastatic colorectal cancer. , 2019, European journal of cancer.

[6]  Tae Won Kim,et al.  Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. , 2019, Clinical colorectal cancer.

[7]  M. Weiser,et al.  Detection of methylated BCAT1 and IKZF1 in stage II/III rectal cancer receiving chemoradiation. , 2019, Journal of Clinical Oncology.

[8]  Jeffrey W. Clark,et al.  Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC). , 2019, Journal of Clinical Oncology.

[9]  A. Bardelli,et al.  Early‐onset colorectal cancer in young individuals , 2018, Molecular oncology.

[10]  D. Tait,et al.  Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. , 2018, Annals of Oncology.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  Tae Yoon Lee,et al.  Simple and Low‐Cost Sampling of Cell‐Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA , 2018, Advanced science.

[13]  Lijun Shen,et al.  Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach. , 2018 .

[14]  J. Edwards,et al.  ctDNA sequencing for early detection of colorectal cancers: Comparative analysis of colon cancer and rectal cancer data. , 2018 .

[15]  G. Beets,et al.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study , 2018, The Lancet.

[16]  Jeffrey W. Clark,et al.  Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC). , 2018 .

[17]  A. El-Shal,et al.  Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients. , 2018, Gene.

[18]  K. Kinzler,et al.  Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study , 2018, Gut.

[19]  D. Tait,et al.  KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer , 2018, Scientific Reports.

[20]  Mingwei Li,et al.  Monitoring colorectal cancer following surgery using plasma circulating tumor DNA , 2018, Oncology letters.

[21]  B. S. Sørensen,et al.  Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Baek.  Laterality: Right-Sided and Left-Sided Colon Cancer , 2017, Annals of coloproctology.

[23]  A. Habr-Gama,et al.  Management of the Complete Clinical Response , 2017, Clinics in Colon and Rectal Surgery.

[24]  Alexandra M. Binder,et al.  Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer , 2017, Gut.

[25]  H. Nielsen,et al.  Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer , 2017, Clinical Cancer Research.

[26]  Grace Q. Zhao,et al.  Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. , 2017 .

[27]  D. Radojkovic,et al.  Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[28]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[29]  M. Büchler,et al.  Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis , 2016, Journal of Gastrointestinal Surgery.

[30]  Richard Emsley,et al.  Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. , 2016, The Lancet. Oncology.

[31]  Angelita Habr-Gama,et al.  The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation , 2015, Oncotarget.

[32]  E. D. de Vries,et al.  Rectal and colon cancer: Not just a different anatomic site. , 2015, Cancer treatment reviews.

[33]  H. Harling,et al.  High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. , 2015, The Lancet. Oncology.

[34]  Y. Wu,et al.  Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer , 2014, British Journal of Cancer.

[35]  H. Zhang,et al.  The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. , 2014, Oncology reports.

[36]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[37]  H. Kuroyanagi,et al.  Laparoscopic surgery for rectal cancer: Current status and future perspective , 2014, Asian journal of endoscopic surgery.

[38]  J. C. S. Silva Neto,et al.  Circulating cell-free DNA in serum as a biomarker of colorectal cancer , 2013, Journal of Clinical Pathology.

[39]  W. Enker,et al.  Long-term Results of Rectal Cancer Surgery with a Systematical Operative Approach , 2013, Annals of Surgical Oncology.

[40]  I. Cree,et al.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers , 2011, British Journal of Cancer.

[41]  E. Urso,et al.  Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy , 2011, Annals of Surgical Oncology.

[42]  L. Påhlman,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[44]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[45]  R. Zeillinger,et al.  Circulating Cell-Free DNA in Plasma of Locally Advanced Rectal Cancer Patients Undergoing Preoperative Chemoradiation: A Potential Diagnostic Tool for Therapy Monitoring , 2008, Disease markers.

[46]  J. Meyerhardt,et al.  Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.

[47]  R. Heald,et al.  Embryology and anatomy of the rectum. , 1998, Seminars in surgical oncology.

[48]  J. Gama-Rodrigues,et al.  Low rectal cancer , 1998, Diseases of the colon and rectum.